Congressmen Call On GAO To Update Behind-The-Counter Class Investigation
This article was originally published in The Tan Sheet
Executive Summary
The Government Accountability Office should update its 1995 study of behind-the-counter drug regulatory schemes in o0ther countries to better educate FDA as it considers a third class of drugs in the U.S., members of the House Energy and Commerce Committee say in a Jan. 16 letter to the GAO
You may also be interested in...
Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO
A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says
Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO
A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says
Behind-The-Counter Class Requires Investment, With Payoff Unclear– GAO
A behind-the-counter drug class in the U.S. is not feasible unless the government addresses some significant logistical challenges, the Government Accountability Office says